Rhophylac Stungulyf, lausn 300 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

rhophylac stungulyf, lausn 300 míkróg

csl behring gmbh - immunoglobulin-anti d - stungulyf, lausn - 300 míkróg

S-Ketamin Pfizer Stungulyf, lausn 25 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

s-ketamin pfizer stungulyf, lausn 25 mg/ml

pfizer aps - esketaminum hýdróklóríð - stungulyf, lausn - 25 mg/ml

Sufenta Stungulyf, lausn 5 míkróg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sufenta stungulyf, lausn 5 míkróg/ml

piramal critical care b.v. - sufentanilum cítrat - stungulyf, lausn - 5 míkróg/ml

Syntocinon Stungulyf, lausn 10 a.e./ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

syntocinon stungulyf, lausn 10 a.e./ml

alfasigma s.p.a. - oxytocinum inn - stungulyf, lausn - 10 a.e./ml

Tranexamsyre Pfizer (Cyklokapron stungulyf, lausn) Stungulyf/innrennslislyf, lausn 100 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

tranexamsyre pfizer (cyklokapron stungulyf, lausn) stungulyf/innrennslislyf, lausn 100 mg/ml

pfizer aps - tranexamic acid - stungulyf/innrennslislyf, lausn - 100 mg/ml

Degarelix Accord Evrópusambandið - íslenska - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - blöðruhálskirtli - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.